Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug‐Loaded Magnetic Solid Lipid Nanoparticles
Drug targeting
Niacinamide
HepG2
HepG2; drug targeting; magnetic nanoparticles; solid lipid nanoparticles; sorafenib
Carcinoma, Hepatocellular
Solid lipid nanoparticles
Antineoplastic Agents
Apoptosis
02 engineering and technology
Humans
Magnetite Nanoparticles
Cell Proliferation
Mitogen-Activated Protein Kinase 1
Drug Carriers
Mitogen-Activated Protein Kinase 3
Phenylurea Compounds
Liver Neoplasms
Dextrans
Hep G2 Cells
Sorafenib
Lipids
Magnetic Resonance Imaging
3. Good health
Magnetic nanoparticles
0210 nano-technology
DOI:
10.1002/adhm.201500235
Publication Date:
2015-06-04T03:23:32Z
AUTHORS (14)
ABSTRACT
Sorafenib is an anticancer drug approved by the Food and Drug Administration for the treatment of hepatocellular and advanced renal carcinoma. The clinical application of sorafenib is promising, yet limited by its severe toxic side effects. The aim of this study is to develop sorafenib‐loaded magnetic nanovectors able to enhance the drug delivery to the disease site with the help of a remote magnetic field, thus enabling cancer treatment while limiting negative effects on healthy tissues. Sorafenib and superparamagnetic iron oxide nanoparticles are encapsulated in solid lipid nanoparticles by a hot homogenization technique using cetyl palmitate as lipid matrix. The obtained nanoparticles (Sor‐Mag‐SLNs) have a sorafenib loading efficiency of about 90% and are found to be very stable in an aqueous environment. Plain Mag‐SLNs exhibit good cytocompatibility, whereas an antiproliferative effect against tumor cells (human hepatocarcinoma HepG2) is observed for drug‐loaded Sor‐Mag‐SLNs. The obtained results show that it is possible to prepare stable Sor‐Mag‐SLNs able to inhibit cancer cell proliferation through the sorafenib cytotoxic action, and to enhance/localize this effect in a desired area thanks to a magnetically driven accumulation of the drug. Moreover, the relaxivity properties observed in water suspensions hold promise for Sor‐Mag‐SLN tracking through clinical magnetic resonance imaging.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (57)
CITATIONS (94)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....